Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-DOTA-(1P-PEG4)
- Development stage
- Preclinical
- Lead developer
- Peking University
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[68Ga]Ga-DOTA-(1P-PEG4) is a radiopharmaceutical diagnostic probe designed for positron emission tomography (PET) imaging of prostate cancer. It consists of a prostate-specific membrane antigen (PSMA)-targeting monomeric ligand conjugated to a polyethylene glycol (PEG4) spacer and a DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelator, which is radiolabeled with the positron-emitting isotope Gallium-68. The probe specifically targets PSMA, a cell-surface protein that is highly overexpressed in prostate cancer cells. The inclusion of the PEG4 chain is intended to optimize the probe's pharmacokinetics by increasing hydrophilicity and potentially improving tumor-to-background ratios. In preclinical studies, this monomeric version serves as a structural baseline to evaluate the advantages of multivalent (dimeric) PSMA tracers in terms of tumor accumulation and renal clearance.
- Other names
- 68Ga-DOTA-(1P-PEG4)Ga-68 DOTA-PEG4-PSMA monomerGa68 DOTA-PEG4-PSMA monomerGa 68 DOTA-PEG4-PSMA monomer
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [68Ga]Ga-DOTA-(1P-PEG4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-DOTA-(1P-PEG4).